Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III r...

por Roden, Michael, Merker, Ludwig, Christiansen, Anita Vedel, Roux, Flavien, Salsali, Afshin, Kim, Gabriel, Stella, Peter, Woerle, Hans J., Broedl, Uli C.
Publicado 2015

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours

por Bahleda, Rastislav, Hollebecque, Antoine, Varga, Andrea, Gazzah, Anas, Massard, Christophe, Deutsch, Eric, Amellal, Nadia, Farace, Françoise, Ould-Kaci, Mahmoud, Roux, Flavien, Marzin, Kristell, Soria, Jean-Charles
Publicado 2015